Abstract: The invention relates to a simple and industrially readily executable method of producing thiazolidine base and salts thereof. In particular, the invention relates to a process for the production of thiazolidine base and salts thereof which is characterized in that hexamethylenetetramine of formula (I) is caused to react with cysteamine or salts thereof of formula (II) in which X(−) represents an acid residue, X(−) being preferably a halide or sulfate.

Abstract: Osmotically derived liposomal vesicles loaded with an active agent are disclosed. Liposomes, including an entrapped osmotic agent, are contacted one or more times with a washing solution which is hypotonic to the entrapped osmotic agent and which contains active agent. The entrapped osmotic agent in the liposome and the active agent in the washing solution are each present in concentrations causing the liposomes to swell, rupture under osmotic pressure, spill osmotic agent into the washing solution and re-form to encapsulate active agent.

Abstract: A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing one or more entrapped solutes, the concentration of such solutes in each aqueous compartment being substantially equal to the concentration of solutes used to prepare the SPLVs. The bilayers of SPLVs are substantially non-compressed. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.

Abstract: An adjuvant composition comprising a small liposome with incubation associated immuno-potentiator such as Lipid A, said composition with incubation associated antigen, and method of preparation and use.

Abstract: A taste moderating composition comprising a liposome associated flavorant and method of preparation and use.

Abstract: A method of treating, by intramammary infusion of liposomes, Brucella spp. infections in an animal by administration of a therapeutically effective amount of aminoglycoside in liposome form, also being a method of administering a therapeutic agent in liposome form to a proximal mammary lymph node or mammary tissue of an animal.

Abstract: Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.

Abstract: Steroidal liposomes comprising a bioactive agent and method for their administration are disclosed, the bilayers of said steroidal liposomes comprising a salt form of a carboxylic acid derivative of a sterol, a salt form of a polycarboxylic acid derivative of a sterol, a salt form of a hydroxy carboxylic acid derivative of a sterol, a salt form of an amino acid derivative of a sterol or a salt form of a poly (amino acid) derivative of a sterol; or a salt form of an organic acid derivative of cholesterol, a vitamin D, a phytosterol, or a steroidal hormone.

Abstract: Methods and compositions are described for the preparation of lipid vesicles, the bilayers of which comprise a salt form of an organic acid derivative of a sterol such as the tris-salt form of a sterol hemisuccinate. The method is rapid, efficient, and does not require the use of organic solvents. The sterol hemisuccinate vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility thus enabling administration in vivo.

Abstract: A multivalent pneumococcal vaccine of the group consisting of immunogenic amounts of purified pneumococcal capsular polysaccharide (substantially absent "C" polysaccharide) of pneumococcal types (Danish designation) 1, 2, 3, 4, 6A, 6B, 7F, 8, 9N, 12F, 14, 18C, 19F, 20, 23F, and 25 and combinations thereof and methods of purifying pneumococcal capsular polysaccharide types 1, 2, 3, 4, 6A, 6B, 7F, 8, 9N, 12F, 14, 18C, 19F, 23F and 25.

Abstract: Substituted Dibenz[b,f][1,4]oxazepin-11-yl pyridinium salts and derivatives thereof useful as intermediates in the preparation of anti-psychotic agents.

Abstract: Unsubstituted, mono-, di- or trisubstituted-11-(1,2,3,6-tetrahydro-substituted-4-pyridyl)-dibenz[b,f][1 ,4]oxazepines, useful as anti-psychotic agents..

Abstract: A method for stabilizing pneumococcal capsular polysaccharide employing glycine or alanine and other amino acids, or albumin, gelatin, protein hydrolysates, and other proteins.

Abstract: A process for the isolation and purification of immunologically active polyribosyl ribitol phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b. The PRP has been purified with ethanol, Cetavlon (hexadecyltrimethyl ammonium bromide) and a phosphate containing adsorbent, hydroxylapatite. The contaminants (nucleic acid, proteins and endotoxins) are removed to the minimum level by a treatment with hydroxylapatite. Also described is a process for the preparation of a combined vaccine containing the PRP (prepared as aforementioned) and B. pertussis antigens. The vaccine elicits anti-PRP antibody and antipertussis antibody (as measured by microagglutination) formations in young animals. This sera with anti-PRP antibody exhibits a strong bactericidal activity.

Abstract: Compounds of metabolites of 3-(4-biphenylylcarbonyl)propionic acid useful as anti-inflammatory and anti-platelet aggregation agents.